A Multicenter, Open-Label, Follow-Up Study to Assess the Long-Term Use of Oral Lacosamide in Study Participants Who Completed EP0034 or SP848 and Received Lacosamide Treatment
Latest Information Update: 29 Nov 2023
At a glance
- Drugs Lacosamide (Primary)
- Indications Epilepsy; Partial epilepsies
- Focus Adverse reactions
- Sponsors UCB Biopharma
- 23 Nov 2022 Planned End Date changed from 1 Aug 2025 to 31 Jul 2025.
- 23 Nov 2022 Planned End Date changed from 1 Aug 2025 to 31 Jul 2025.
- 23 Nov 2022 Planned primary completion date changed from 1 Aug 2025 to 31 Jul 2025.